- Horizons and Jerusalem-based OurCrowd lead US$24 million Series B funding round
- Funding will go towards the expansion of a third-phase clinical trial of a nasal spray aimed at treating and preventing Covid-19
Read more here.
- Horizons and Jerusalem-based OurCrowd lead US$24 million Series B funding round
- Funding will go towards the expansion of a third-phase clinical trial of a nasal spray aimed at treating and preventing Covid-19
Read more here.
![[Sufresca in NoCamels] Natural spray adds weeks to life of fresh fruit and veg](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
